Plaque disruption with superimposed thrombosis is the main cause of acute coronary events such as acute myocardial infarction and unstable angina. Among other factors, tissue factor seems to play an important role determining plaque thrombogenicity. Tissue factor is a potent initiator of the coagulation cascade situated within the vessel wall and is highly exposed to the blood after plaque rupture. Several mediators involved in the process of atherosclerotic plaque formation are capable of inducing tissue factor expression in cells such as monocytes, macrophages and endothelial cells, which under normal conditions do not express tissue factor or to a limited extent only. The increased expression of tissue factor is not limited to the plaque but is also found in circulating monocytes in patients with acute coronary syndromes. In addition, studies have shown an important contribution of tissue factor in the pathogenesis of thrombosis and restenosis after balloon angioplasty. Recent basic studies focus on the therapeutic inhibition of tissue factor. Specific and non-specific inhibitors of tissue factor or the tissue factor / factor VIIa complex have been developed or identified, and have been tested in experimental studies. Clinical studies are currently being initiated. In this review, we present the current knowledge on the role of tissue factor in atherosclerosis, arterial intervention and potential pharmacological approaches, with focus on acute coronary syndromes.
Introduction
with subsequent thrombosis [3, [5] [6] [7] [8] . Plaque content determines its thrombogenicity, and tissue factor (TF) is Plaque disruption with superimposed thrombosis is the thought to play a key role. In this review, we outline the main cause of acute coronary syndromes including uncurrent understanding of the role of TF in atherosclerotic stable angina, myocardial infarction and sudden cardiac diseases with focus on acute coronary syndromes. death [1] [2] [3] . The composition and vulnerability of atherosclerotic plaques, rather than their volume or the severity of a stenosis, seem to be the most important determinants of 2. Physiology of tissue factor plaque rupture [3] . Foam cells and smooth muscle cell infiltration, and connective tissue deposition (type I-III TF is a 263-residue membrane-bound glycoprotein lesions according to Stary et al. [4] ) mark early lesions. As composed of a 219-residue extracellular domain, a single these lesions grow into 'softer' plaques with a high transmembrane sequence and a short cytoplasmic domain extracellular lipid and cholesterol ester content and a [9, 10] . Thus, TF is a surface-bound, transmembrane progressively thinner fibrous cap (types IV-V, 'atheroma'), glycoprotein that is normally not present in or exposed to they become more vulnerable to disruption [1, 2, 4, 5] .
the circulation or in contact with it. The location of TF on Inflammation may be the trigger for rupture of the lesion, plasma membranes enables a nidus of coagulation to remain fixed at the site of injury, which may explain why coagulation does not disseminate from its initiation site q Professor F.W.A. Verheugt acted as guest editor for this manuscript.
[11]. The exposure of cell surfaces expressing TF to plasma proteins leads to the binding of factor VII to TF contains a heparin-binding site, is not clear. TFPI is mainly [11] [12] [13] . TF and factor VII have a high affinity for each synthesized by vascular endothelial cells [17] and the other and neither component alone has procoagulant majority (50-90%) of the intravascular pools of this activity at physiological concentrations. The complex TFinhibitor is associated with these cells [18, 19] . Less than factor VII may be activated into the complex TF-factor 2.5% of total TFPI is located in platelets and the remaining VIIa by free factor VIIa and / or by already formed TFin plasma in a free or lipoprotein-associated form [20, 21] . factor VIIa complexes. The complex TF-factor VIIa further activates free factor VII. These mechanisms describes the TF-mediated factor VII autoactivation. The TF-factor VIIa 3. Cellular expression of tissue factor complex rapidly catalyzes the activation of factor X and, at a lower rate, of factor IX. Activated factor IX, in the In normal vessels, TF is synthesized at the subendothelipresence of its co-factor factor VIII, cleaves additional al level by smooth muscle cells in the tunica media and factor X to factor Xa. Eventually, these processes lead to predominantly by fibroblasts in the adventitia surrounding the generation of thrombin, which catalyzes the formation the vessels [22, 23] . Hence, disruption of the endothelial of fibrin and its polymerization to form a fibrin clot (see layer exposes TF to circulating blood. Peripheral blood Fig. 1 ).
cells and endothelium do not express TF under normal TF is present in vascular adventitia, organ capsules, conditions, consistent with the hypothesis that expression epidermis, and mucosal epithelium [14] . Prominent expresof TF is anatomically separated from blood. However, in sion of TF has been observed in cardiac myocytes, the response to a variety of stimuli, TF expression is induced cerebral cortex, renal glomeruli, and the lung [14] . TF is in different cell-types and this has been the subject of thus expressed at tissue barriers between the body and the many studies. Some important findings are listed below. environment, where it fulfils a hemostatic role in activating coagulation when the vascular integrity is disrupted.
Monocytes and macrophages
The endogenous inhibitor of the TF-factor VIIa complex is tissue factor pathway inhibitor (TFPI) . TFPI is a KunitzIn addition to increasing procoagulant activity with age type protease inhibitor consisting of three tandem Kunitz [24] different mechanisms may trigger increased domains [15] . TFPI inhibits TF in a two-step mechanism.
procoagulant activity by mononuclear cells. It binds via its second Kunitz domain to the active site of Lymphocytes may interact with monocytes and macrofactor Xa, thus inhibiting the proteolytic capacity of factor phages by two main parallel and independent models of Xa. The following step is the inhibition of the catalytic cellular interaction [25] . One pathway is mediated by activity of TF-factor VIIa complexes by formation of the specific cytokines like interleukin (IL)-2, tumor necrosis quaternary complex TF-factor VIIa / TFPI-factor Xa [15] .
factor-b and interferon-g. These cytokines, produced by Due to its factor Xa dependency, inhibition by TFPI is Th1 cells, induce TF expression in mononuclear cells [26] . slow but it completely inhibits TF / factor VIIa activity Conversely, inhibition of TF expression is mediated by [16] . The function of the third Kunitz domain, that Th2 cell derived cytokines IL-4, IL-13 and IL-10 and may be important in preventing thrombosis [26, 27] . The second pathway is thought to be due to T cell binding to the CD40 receptor present on the membranes of monocytes and macrophages [28] , which induces active TF expression on human monocytes and macrophages [29, 30] . In addition to cell-induction, C-reactive protein, of which plasma levels are increased in patients with unstable angina [31] , stimulates monocyte TF expression [32] . Furthermore, an isoform of platelet-derived growth factor (PDGF), PDGF-BB, is released by activated platelets and induces TF expression on the surface of both vascular smooth muscle cells and human monocytes [33, 34] . Another feature of PDGF-BB is the stimulation of vascular smooth muscle cells to produce monocyte chemoattractant protein-1 [35] , which is produced within the plaque and most likely involved in the recruitment of monocytes into the plaque [36] . It also leads to a dose-and time-dependent induction of TF expression in arterial smooth muscle cells and monocytes [34, 37] . Recently, it has been demonstrated during activation [38] . These findings indicate a positive feedback mechanism of additional TF mediated thrombin monocytes and possibly polymorphonuclear leukocytes to generation.
platelets, making the platelets capable of triggering and Monocyte-derived macrophages that are enriched with propagating thrombosis [53] . lipids or intracellular free cholesterol (foam cells) produce Thus, monocytes and macrophages not only play an greater amounts of TF compared to non-lipid-enriched important role in the pathogenesis of atherosclerosis [54] , macrophages [39, 40] . Conflicting results however, have they also are potent activators of blood coagulation been reported on the effect of lipoproteins on the through the ability to express TF upon activation. This procoagulant activity of monocytes and macrophages. might aggravate or even trigger thrombosis in patients with Studies have shown no [41, 42] or even an inhibitory [43] acute coronary syndromes. effect, whereas others demonstrated an induction by native or oxidized low-density lipoprotein of TF expression and 3.2. Vascular smooth muscle cells activity in mononuclear cells [44, 45] . Experimental exposure of monocytes to very low-density lipoprotein and high Platelet-derived growth factor-BB, as mentioned previdensities lipoprotein has resulted either in no effect [41] or ously, and thrombin are capable of inducing TF expression in increased TF activity [43, 44] . More uniform are the on cultured vascular smooth muscle cells [33, 55] . Howreports concerning acetylated low-density lipoprotein, ever, the induction of surface-bound active TF represents which is a potent inducer of TF expression in monocytes only a small percentage (620%) of total cellular TF [55] . and macrophages [40, 42, 46] . This could represent an adaptive mechanism for limiting Monocytes from patients with unstable angina showed a the procoagulant potential of the vessel wall. The remainhigher TF like procoagulant activity in vitro than control der of TF was present in an intracellular pool and as subjects or patients with stable angina [47] . This activity encrypted surface TF [55] , which may provide a rich correlated with activation of the coagulation system as source of TF after smooth muscle cell damage, such as assessed by fibrinopeptide A plasma levels. Conceivably, plaque rupture or balloon injury. Native low-density the exposure of lymphocytes to an (unknown) inducer lipoprotein also increased surface TF on human arterial triggers a series of reactions leading to monocyte activasmooth muscle cells, but surface TF activity remained tion, increased thrombin generation and instability of limited [56] . Ligation of the CD40 receptor, present on the coronary artery disease [47] . A higher monocyte TF-like membrane of smooth muscle cells, augments the expresactivity was shown in patients who had recently suffered sion of both TF protein and TF activity on the surface of an acute myocardial infarction compared to healthy conhuman vascular smooth muscle cells [57] . Because TF and trols [48] . This was paralleled by an increase in plasma CD40 colocalize on lesional smooth muscle cells in human TFPI activity, which may be of importance for mainteatheroma, this pathway may contribute to the TF expresnance of the hemostatic balance. However, in these sion during inflammatory responses of atherogenesis and patients, heparin-induced increases in plasma TFPI levels arterial injury. may be partly responsible for this effect. Unstable angina patients exhibit higher levels of TF expression both in 3.3. Endothelial cells unstimulated and endotoxin-stimulated monocytes, compared to patients with stable angina and acute myocardial Many studies have investigated the induction of TFinfarction [49] . Only in the unstable angina patients mediated procoagulant activity in cultured human endomonocyte activation was correlated with increased fibrinothelial cells, and several stimulating factors have been gen levels [49] . Balloon angioplasty in stable and unstable identified including interleukins [58] [59] [60] , tumor necrosis angina patients seems to have no significant effect on the factor-a [58, [60] [61] [62] , endotoxin [63, 64] , and shear stress level of TF expression in stimulated and unstimulated [65] . In some studies no or only minimal TF activity at the monocytes within the first 24 h after the procedure [50] .
(apical) endothelial cell surface was detected after stimulaIncreased monocyte TF expression is seen in patients with tion with tumor necrosis factor [62, 66, 67] . TF expression an acute coronary syndrome and less pronounced, in was more prominently localized at the subendothelial patients with chronic stable angina [51] .
matrix [67] , at the basolateral surface [62] , or it remained An interesting experiment demonstrated abundant TF intracellular in the endothelial cell [67] . This suggests a staining in thrombi formed in human blood that was tightly regulated TF expression in endothelial cells which exposed to surfaces which either was devoid of TF or did may only gain access to the blood after disruption of the not contain stainable TF (see Fig. 2 ) [52] . 'Blood-borne' endothelial monolayer. Some pathways of TF expression TF from neutrophils and monocytes may be thrombogenic described for monocytes-macrophages and / or vascular and involved in thrombus propagation at the site of smooth muscle cells, have also been identified in endovascular injury. Moreover, it may serve as a mechanism of thelial cells. Oxidized low-density lipoprotein is a potent initiating thrombus formation independent of procoagulstimulus for TF expression in cultured human endothelial ants in the atherosclerotic plaque. This hypothesis is cells [68] . Ligation of the CD40 receptor (expression of supported by the demonstration of transfer of TF from which might be upregulated after exposure with interferon- g) by T cells or activated platelets increases TF expression TF expression was shown in all stages of atherosclerotic on endothelial cells [69, 70] . Platelets have also been lesions [72, 74, 75] . Abundant TF protein (see Fig. 3 ) and shown to stimulate TF production in human endothelial TFPI was found in the extracellular matrix of the necrotic cells [71] .
core of the plaques [22, [73] [74] [75] 77, 79, 81, 82] . TF found in the lipid-core is thought to be largely derived from the macrophages present in the plaque [73, 81, 82] . However, a 4. Tissue factor in atherosclerotic plaques contribution of vascular smooth muscle cells and endothelial cells cannot been ruled out. Extracellular TF in TF was identified in atherosclerotic plaques from variapoptotic areas is derived from shed membrane apoptotic ous arterial sites. TF-antigen, TF-activity as well as TFmicroparticles originating from macrophages and lymphomRNA have been detected in different cell types within cytes [82] . This accounts for almost all the TF activity of the plaque including endothelial cells, vascular smooth the plaque extract. muscle cells, monocytes and especially in macrophages or TF in atherosclerotic plaques may play a major role in foam cells (see Fig. 3 ) [22, [72] [73] [74] [75] [76] [77] , which represent up to the initiation of thrombus formation. Fibrin deposition in 60% of the cells in the plaque [78] . TF colocalizes with atherosclerotic intima is occasionally located around foamy TFPI in these cells [79] . The presence of TFPI in human or non-foamy macrophages and smooth muscle cells, atherosclerotic plaques is associated with reduced TF which overexpress TF [74] . Compared to fibrous, collagenactivity [80] .
rich lesions and other arterial components, more in vitro platelet deposition and more intense TF staining are found intervention in patients with stable or unstable coronary on lipid-rich atheromatous core material [81] .
disease, resulted in elevated soluble TF levels measured in In human coronary atherectomy specimens, concentrathe coronary sinus after 4 h. This was accompanied by tions of TF antigen and activity were found to be higher in increased levels of thrombin-antithrombin complexes after plaques taken from patients with de novo angina, unstable 24 h [100] . However, this increase was not observed by the angina or myocardial infarction as compared to stable study of Marco et al., who did not find significant changes patients or patients with re-stenosis [83] [84] [85] [86] . In addition, in plasma levels of TF and thrombin-antithrombin comthrombus was detected only in TF-positive plaques (see plexes after angioplasty in patients with stable and unstable Fig. 3 ) [77] and fibrin deposition was mainly observed angina [90] . around the massive infiltration of TF-positive macrophages TF induction in vascular smooth muscle cells may in patients with unstable angina [86] . These findings importantly contribute to thrombosis associated with arterisuggest a role of TF in the progression to unstable al intervention. Intimal smooth muscle cell expression of coronary syndromes.
TF plays an important role in the fibrin-rich thrombus formation and subsequent neointimal development following balloon injury to rabbit aortas [101] . TF overexpressing smooth muscle cells in a rat arterial neointima 5. Plasma levels of soluble tissue factor in acute accelerated reendothelialization and increased smooth muscoronary syndromes cle cell migration via an autocrine manner in vivo and in vitro, of which the in vitro response occurred by Significantly higher levels of circulating soluble TF are coagulation-dependent and -independent pathways. This found in patients with acute myocardial infarction and contributed to enhanced intimal thickening [102] . Arterial unstable angina compared to patients with stable angina balloon injury in normal rabbit and rat aortas resulted in a and control subjects [87] [88] [89] [90] . It is not certain, however, if rapid increase (after 1 or 2 h) in TF-mRNA both in the soluble TF in blood reflects surface-associated TF or the media and adventitia, associated with induced TF activity potential for TF mediated activation of coagulation. A in the media [103] [104] [105] that persisted for 24 h after injury significant decrease of TF levels was seen after successful [104, 106] . Thrombin generation was attenuated in injured treatment of the acute coronary syndrome, except in vessels preincubated with an antibody to rabbit TF [106] . patients with acute myocardial infarction with prodromal Moreover, TF expression also persisted during the subunstable angina whose TF levels remained high after 2 sequent weeks in smooth muscle cells, which proliferated weeks. Moreover, patients with prodromal unstable angina to form the neointima [105] . Balloon angioplasty in before the acute myocardial infarction showed higher TF porcine coronary arteries resulted in a bi-phasic increase of levels than in patients with sudden onset of the infarction TF antigen and activity in the vascular smooth muscle cells [87, 88] . This may reflect repeated episodes of coronary of the media, first peaking between 1 and 24 h with a thrombosis. Plasma levels of free TFPI [89, 91, 92] , as well second increase at 4 weeks after angioplasty [107] . In a as TFPI-activity [93] are increased in patients with an study by Gertz et al., neointimal TF expression, induced by acute coronary syndrome, compared to control subjects or balloon angioplasty in rabbit femoral and porcine coronary patients with stable angina.
arteries, persisted 1 month after intervention [108] . HowThese results express the hypercoagulable state of these ever, Giesen et al. recently found prominent medial TF patients, which is inhibited by TFPI. The source of staining only 24 h after first balloon injury in normal rat circulating TF is unclear, but enhanced TF expression in aortas [99] . In addition, despite abundant TF in the coronary atherosclerotic plaques and circulating monocytes neointima before and after a second balloon inflation 2 are likely candidates.
weeks following the first injury, this was not accompanied with an increased luminal TF activity and only small platelet-fibrin microthrombi were present after the double injury. Possible explanations for this phenomenon are that 6. Tissue factor and (coronary) artery interventions active TF is rapidly complexed with inhibitors such as TFPI, that active TF does not appear to be anchored to the Balloon angioplasty results in plaque fracturing and arterial wall and can be readily washed away, or due to dissection, and the extent of vascular injury appears to be induction of fibrinolytic activity [99] . related to the extent of thrombin generation [94] [95] [96] .
Comparable to PDGF, TF in complex with factor VIIa, Exposure of circulating clotting factors to procoagulants induces chemotactic migration of cultured rabbit smooth within the vessel wall, especially after formation of a muscle cells [109, 110] . neointima, accelerates thrombus formation [97] [98] [99] . This is In summary, these studies suggest that TF not only of particular clinical importance as patients develop a influences the acute thrombotic response, but also may neointima after angioplasty, and a significant proportion contribute to atherogenesis, coronary restenosis or proneeds re-intervention. In one clinical study, percutaneous longed thrombin generation after interventions.
7. Therapeutic approaches antagonist of membrane bound TF by alanine substitution of lysine residues 165 and 166 [123] . This molecule, Two groups of agents inhibiting TF or TF / factor VIIa termed hTFAA, binds factor VIIa and greatly reduces the complex have been developed and tested. The first group catalytic capacity of activated factor X compared to the contains specific inhibitors of TF whether or not in complex TF / factor VIIa. When administered to rabbits complex with factor VIIa. The second group includes a undergoing balloon carotid arterial injury, hTFAA showed variety of drugs with non-specific TF inhibiting properties. potent antithrombotic effects while causing smaller increases in bleeding tendency relative to heparin doses of 7.1. Specific inhibitors of tissue factor and tissue factor / equal antithrombotic potential [123] . factor VIIa complex 7.1.4. Recombinant tissue factor pathway inhibitor 7.1.
Active site inactivated recombinant factor VIIa
Of all agents inhibiting the extrinsic coagulation pathAdministration of active site inactivated recombinant way, recombinant TFPI (rTFPI) is the most extensively factor VIIa (factor VIIai) results in a highly stable TF / investigated drug. On human atherosclerotic arterial segfactor VIIai complex that is unable to initiate coagulation. ments, it reduced significantly both platelet and fibrinogen However, even at high concentrations, this protein does not deposition [117] . When administered with recombinantreplace TF bound to factor VIIa [16] . It competes with plasminogen activator in a dogs model of electrically factor VIIa for TF binding and thus a certain amount of induced arterial thrombosis, rTFPI attenuated or even active TF / factor VIIa complexes may be formed during prevented reocclusion and markedly inhibited cyclic flow administration of factor VIIai [16] . In animal models, variations [124, 125] . However, in a different study by intravenous, topical and intracarotid administration of Lefkovits et al., rTFPI or DEGR-VIIa compared to tick factor VIIai exerted a pronounced antithrombotic effect, anticoagulant peptide, administered after thrombolytic which was not accompanied by bleeding or a prolonged treatment with recombinant-plasminogen activator, did not bleeding time [111] [112] [113] . In addition, a 3-day infusion of prevent acute reocclusion in a similar model [116] . Differ-DEGR-VIIa (a drug with comparable mechanism and ences in methodology and thrombus preparation may be function as factor VIIai) following balloon angioplasty responsible for these discrepancies. Therefore, the value of significantly reduced neointimal formation in rabbit inhibiting the extrinsic TF-dependent pathway as adjuncatherosclerotic femoral arteries [114] . Administration of tive treatment to a thrombolytic agent, remains to be factor VIIai during sequential balloon injury to the rabbit established. Most experimental studies using rTFPI, inabdominal aorta, reduced both fibrin deposition and loss of vestigated the inhibitory properties of this agent on thromlumen. The extrinsic coagulation cascade may therefore bosis and restenosis in arteries undergoing balloon angiopcontribute to the blood vessel remodeling response, followlasty or intimectomy. rTFPI markedly inhibited fibrin ing balloon injury, that is independent of neointimal formation and accumulation of thrombus at the site of growth but leads to extensive loss of lumen [115] . Howinjury [89, 126] . The same findings were reported in a ever, in combination with a thrombolytic agent, factor recent study on local gene transfer by a vector encoding VIIai did not improve the results in a dog model of human TFPI at the site of balloon injury in porcine carotid thrombolysis [116] .
arteries [127] . This even prevented platelet-dependent thrombosis under increased shear stress without detectable 7.1.2. Monoclonal antibodies hemorrhagic risk. However, it takes at least a few hours Monoclonal antibodies to TF, markedly reduce plaque before a transferred gene becomes expressed as a protein thrombogenicity in human arterial segments [117] . In and even longer before the protein reaches a concentration rabbits, these antibodies prevented thrombus formation in that is sufficient for a biological effect. rTFPI gene transfer carotid arteries [118] , reduced thrombotic occlusions in in combination with rTFPI irrigation in the initial 24 h everted femoral arteries [119] , and significantly shortened after angioplasty may overcome this shortcoming, and has lysis time and decreased reocclusion rates following tissuerecently been investigated [128] . Whereas each method plasminogen activator administration in a model of carotid separately led to a significant reduction, the combination of thrombosis [120] . Recently, it was suggested that these these two methods achieved an additional reduction of antibodies reduce myocardial ischemia / reperfusion injury neointima formation after balloon angioplasty in rabbit by reducing TF-initiated intravascular thrombosis [121] aortas. Other studies administered rTFPI via (local) bolus and by inhibiting thrombin-mediated inflammation reinjection or continued infusion varying from 1 to 7 days sulting in decreased chemokine expression and leukocytes after angioplasty or intimectomy in different animal recruitment [122] . models, and histological examination was performed 3-4 weeks after arterial intervention [89, 114, [129] [130] [131] . All 7.1.3. Soluble recombinant human tissue factor experiments showed a significant reduction in neointimal Kelley et al. used a soluble form of human TF, the formation or intimal hyperplasia in rTFPI-treated animals 219-residue extracellular domain, and converted it into an compared to controls. As rTFPI reduces fibrin and throm-bus formation, different mechanisms may contribute to the burst of thrombin generation as a rebound phenomenon inhibition of intimal hyperplasia and restenosis. Fibrin and after abrupt cessation of unfractionated heparin administrafibrin fragments are chemotactic for smooth muscle cells in tion [146] . vitro [132] . Thrombin has been shown to activate platelets producing PDGF, and both thrombin and PDGF stimulate 7.2.2. Lipid lowering treatment smooth muscle cell proliferation [96, 133] . In addition, the Dietary lipid lowering reduces TF expression by cells migration of cultured rabbit aortic smooth muscle cells, (predominantly macrophages) present in rabbit atheroma induced by the complex TF / factor VIIa, was markedly [147] . inhibited by rTFPI [110] . It has also been reported that Data regarding the effects of n23 fatty acids on TF rTFPI alone prevented the proliferation of cultured human activity are conflicting. Some studies found that dietary neonatal aortic smooth muscle cells [134] . Therefore, enrichment with fish oil or administration of n23 fatty rTFPI seems to reduce neointimal development through acids inhibit stimulated and non-stimulated monocytes to both a direct and indirect action on smooth muscle cells.
express TF activity in healthy subjects [148, 149] , patients with hypertriglyceridemia [149] and nonhuman primates 7.1.5. Nematode anticoagulant protein c2 [150] . Others reported no effect of n23 fatty acids on A peptide with a mode of action comparable to TFPI is resting or endotoxin-stimulated mononuclear cells in healnematode anticoagulant protein c2 (NAPc2), isolated from thy volunteers [151] , and that an increased dietary intake the saliva of the hookworm Ancylostoma caninum [135] .
even resulted in a tendency towards a stimulation of In contrast to TFPI, NAPc2 binds to factor X at a site monocyte procoagulant activity [152] . distinct from its catalytic center, therefore obviating the Treatment with HMG-CoA reductase inhibitors (statins) need for formation factor Xa prior to forming the resultant reduced monocyte TF expression in hypercholesterolaemic binary complex which inhibits the TF / factor VIIa compatients [153] , and attenuated TF antigen, TF activity and plex. A recombinant form of NAPc2 has been tested in a TF-mRNA levels in cultured stimulated and unstimulated pig and rat model of acute coronary and carotid thromhuman macrophages, differentiated from monocytes [154] . bosis, and was significantly more potent than low molecu-
The latter results indicate that statins interfere with the TF lar weight heparin [136] . To prevent deep venous thrombiosynthesis. Nordøy et al. showed in patients with combosis, recombinant NAPc2 showed promising results in bined hyperlipidemia a significant reduction of plasma low patients undergoing knee arthroplasty [137] . At a dose of density lipoprotein levels induced by simvastatin. This was 3.0 mg / kg bodyweight, administered within 1 h after paralleled by a reduction of TFPI activity, which was surgery, the rate of deep venous thrombosis in this group possibly due to a decrease in low density lipoprotein-TFPI of patients was 12.2%, which is half the rate achieved with complexes [155] . The free form of plasma TFPI was the current standard treatment with low molecular weight unchanged by statins alone but decreased modestly by heparin, with no excess in major bleedings. This drug is adding n23 fatty acids to statin treatment. Berrettini et al. currently investigated in different clinical trials on preventalso showed a significant correlation between TFPI activity ing arterial thrombosis, including in patients undergoing and low density lipoproteins [156] . 138, 140] by displacing the inhib-L-Arginine, the endogenous precursor of nitric oxide, itor from endothelial cell surface glycosaminoglycans with significantly blunted TF expression in stimulated monosubsequent release into the circulation and formation of cytes after angioplasty of the iliac arteries in a rabbit heparin-TFPI complexes [141, 142] . In addition, heparin model of atherosclerosis [157] . inhibits monocyte TF expression after binding to activated Cyclosporin A inhibited procoagulant activity in stimumonocytes [143] . However, heparin releasable TFPI anlated and unstimulated cultured human monocytes and tigen and activity are depleted during repeated or conmacrophages [158] , and in a dose-dependent manner tinued intravenous heparin administration [144] and during reduced monocyte TF activity and TF-mRNA expression percutaneous transluminal coronary angioplasty [145] . A in cardiac transplant recipients [159] . rapid decrease in TFPI concentration impairing physiologiRecently, it has been demonstrated that smoking incal vascular thromboresistance may contribute to a sudden creases TF immunoreactivity in atherosclerotic plaques and 
